Stripey
2021-10-09
Miss it at $30
ChemoCentryx's stock jumps 88% on FDA approval of TAVNEOS for treatment of vasculitis
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":821269842,"tweetId":"821269842","gmtCreate":1633748386018,"gmtModify":1633748386143,"author":{"id":4096341081825100,"idStr":"4096341081825100","authorId":4096341081825100,"authorIdStr":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":4,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Miss it at $30</p></body></html>","htmlText":"<html><head></head><body><p>Miss it at $30</p></body></html>","text":"Miss it at $30","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/821269842","repostId":1100113443,"repostType":4,"repost":{"id":"1100113443","kind":"news","pubTimestamp":1633699552,"share":"https://www.laohu8.com/m/news/1100113443?lang=&edition=full","pubTime":"2021-10-08 21:25","market":"us","language":"en","title":"ChemoCentryx's stock jumps 88% on FDA approval of TAVNEOS for treatment of vasculitis","url":"https://stock-news.laohu8.com/highlight/detail?id=1100113443","media":"seekingalpha","summary":"Update: Shares surge 80% in morning trading as trading resumed after FDA approval.\nChemoCentryx(NASD","content":"<p><b>Update</b>: Shares surge 80% in morning trading as trading resumed after FDA approval.</p>\n<p>ChemoCentryx(NASDAQ:CCXI)announcesthat the FDA has approved TAVNEOS (avacopan), an orally administered selective complement 5a receptor inhibitor, as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA vasculitis), in combination with standard therapy.</p>\n<p>The approval was supported by the results of the Phase III ADVOCATE trial. The study met its primary endpoints of disease remission at 26 weeks and sustained remission at 52 weeks.</p>\n<p>TAVNEOS (avacopan) is also approved for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis in Japan. The regulatory decision in Europe following the EMA review is expected by the end of 2021.</p>\n<p>ANCA-associated vasculitis is a systemic autoimmune disease, resulting in organ damage and failure, with the kidney as the major target, and is often fatal if not treated.</p>\n<p>CCXI shares tumbled 6% in premarket before they were halted for trading, which will resume at 7:30 am ET.</p>\n<p><img src=\"https://static.tigerbbs.com/6fa60267fef48df3f0a9f9c8658f1d60\" tg-width=\"1183\" tg-height=\"561\" width=\"100%\" height=\"auto\"></p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ChemoCentryx's stock jumps 88% on FDA approval of TAVNEOS for treatment of vasculitis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChemoCentryx's stock jumps 88% on FDA approval of TAVNEOS for treatment of vasculitis\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-08 21:25 GMT+8 <a href=https://seekingalpha.com/news/3750870-fda-approves-chemocentryxs-tavneosfor-treatment-of-vasculitis><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Update: Shares surge 80% in morning trading as trading resumed after FDA approval.\nChemoCentryx(NASDAQ:CCXI)announcesthat the FDA has approved TAVNEOS (avacopan), an orally administered selective ...</p>\n\n<a href=\"https://seekingalpha.com/news/3750870-fda-approves-chemocentryxs-tavneosfor-treatment-of-vasculitis\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CCXI":"ChemoCentryx"},"source_url":"https://seekingalpha.com/news/3750870-fda-approves-chemocentryxs-tavneosfor-treatment-of-vasculitis","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1100113443","content_text":"Update: Shares surge 80% in morning trading as trading resumed after FDA approval.\nChemoCentryx(NASDAQ:CCXI)announcesthat the FDA has approved TAVNEOS (avacopan), an orally administered selective complement 5a receptor inhibitor, as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA vasculitis), in combination with standard therapy.\nThe approval was supported by the results of the Phase III ADVOCATE trial. The study met its primary endpoints of disease remission at 26 weeks and sustained remission at 52 weeks.\nTAVNEOS (avacopan) is also approved for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis in Japan. The regulatory decision in Europe following the EMA review is expected by the end of 2021.\nANCA-associated vasculitis is a systemic autoimmune disease, resulting in organ damage and failure, with the kidney as the major target, and is often fatal if not treated.\nCCXI shares tumbled 6% in premarket before they were halted for trading, which will resume at 7:30 am ET.","news_type":1},"isVote":1,"tweetType":1,"viewCount":387,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":11,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/821269842"}
精彩评论